Cargando…

The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?

Background: A National human papilloma virus (HPV) Vaccination Programme for the prevention of HPV infection and associated disease using the quadrivalent HPV vaccine (4vHPV) has been funded and implemented in Australia since 2007, initially for girls only and extended to boys in 2013, with uptake r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Cyra, Brotherton, Julia ML, Pillsbury, Alexis, Jayasinghe, Sanjay, Donovan, Basil, Macartney, Kristine, Marshall, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Centre for Disease Prevention and Control (ECDC) 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194907/ https://www.ncbi.nlm.nih.gov/pubmed/30326995 http://dx.doi.org/10.2807/1560-7917.ES.2018.23.41.1700737

Ejemplares similares

Single-dose nonavalent HPV vaccine: Need of the hour
por: Pal, Manidip, et al.
Publicado: (2020)

Sensitivity of Human Papillomavirus (HPV) Lineage and Sublineage Variant Pseudoviruses to Neutralization by Nonavalent Vaccine Antibodies
por: Godi, Anna, et al.
Publicado: (2019)

Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus
por: Toh, Zheng Quan, et al.
Publicado: (2019)

Herpes zoster vaccination in Australia: what’s available and who benefits?
por: Jayasinghe, Sanjay, et al.
Publicado: (2020)

Nonavalent human papillomavirus vaccination as a treatment for warts in an immunosuppressed adult
por: Ferguson, Sara B., et al.
Publicado: (2017)

Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France
por: Riethmuller, Didier, et al.
Publicado: (2015)

Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine
por: Petry, Karl-Ulrich, et al.
Publicado: (2018)

Childhood erythrodermic lichen planus pemphigoides after nonavalent human papillomavirus vaccination
por: Pizzatti, Laura, et al.
Publicado: (2020)

Head-to-Head Comparison of Bi- and Nonavalent Human Papillomavirus Vaccine-Induced Antibody Responses( )
por: Arroyo Mühr, Laila Sara, et al.
Publicado: (2022)

Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain
por: De La Fuente, Jesús, et al.
Publicado: (2019)

Taking stock and looking ahead: Behavioural science lessons for implementing the nonavalent human papillomavirus vaccine
por: Forster, Alice S., et al.
Publicado: (2016)

Potential impact of a nonavalent anti HPV vaccine in Italian men with and without clinical manifestations
por: Bosco, Liana, et al.
Publicado: (2021)

Nonavalent Human Papillomavirus Vaccination as a Treatment for Skin Warts in Immunosuppressed Adults: A Case Series
por: BOSSART, Simon, et al.
Publicado: (2020)

Impact of HPV vaccination: Achievements and future challenges()
por: Brotherton, Julia M.L.
Publicado: (2019)

The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia
por: Uusküla, Anneli, et al.
Publicado: (2013)

Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis
por: Choi, Horace C. W., et al.
Publicado: (2018)

Stakeholder Perspectives of Australia’s National HPV Vaccination Program
por: Swift, Caitlin, et al.
Publicado: (2022)

Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain
por: Perez, S., et al.
Publicado: (2017)

Age-Related Changes in the Fraction of Cervical Intraepithelial Neoplasia Grade 3 Related to HPV Genotypes Included in the Nonavalent Vaccine
por: Giannella, Luca, et al.
Publicado: (2019)

Human Papillomavirus Infections in Cervical Samples From HIV-Positive Women: Evaluation of the Presence of the Nonavalent HPV Genotypes and Genetic Diversity
por: Sias, Catia, et al.
Publicado: (2020)

Effective HPV vaccination coverage in Australia by number of doses and two-dose spacing: What if one or two doses are sufficient?
por: Smith, Megan A., et al.
Publicado: (2021)

Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico
por: Ortiz, Ana Patricia, et al.
Publicado: (2017)

Rationalizing the HPV vaccination schedule: A long road to a worthwhile destination
por: Brotherton, Julia ML.
Publicado: (2019)

Correction to: Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain
por: Perez, S., et al.
Publicado: (2018)

Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in Sicily
por: Capra, Giuseppina, et al.
Publicado: (2017)

Correction: Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico
por: Ortiz, Ana Patricia, et al.
Publicado: (2018)

Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines
por: Pillsbury, Alexis, et al.
Publicado: (2023)

The short term safety of COVID‐19 vaccines in Australia: AusVaxSafety active surveillance, February – August 2021
por: Deng, Lucy, et al.
Publicado: (2022)

Letter: Impact of the COVID-19 pandemic on pharmacist-administered vaccination services
por: Patel, Cyra, et al.
Publicado: (2021)

Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later – an exploratory study
por: Gilca, Vladimir, et al.
Publicado: (2018)

Active surveillance of 2017 seasonal influenza vaccine safety: an observational cohort study of individuals aged 6 months and older in Australia
por: Pillsbury, Alexis J, et al.
Publicado: (2018)

Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program
por: Garland, Suzanne M, et al.
Publicado: (2011)

Monitoring the impact of HPV vaccine in males—Considerations and challenges
por: Brotherton, Julia M.L., et al.
Publicado: (2016)

Disseminated varicella zoster virus infection following live attenuated herpes zoster vaccine: descriptive analysis of reports to Australia’s spontaneous vaccine pharmacovigilance system, 2016–2020
por: Li-Kim-Moy, Jean, et al.
Publicado: (2023)

Study protocol: Yarning about HPV Vaccination: a qualitative study of factors influencing HPV vaccination among Aboriginal and Torres Strait Islander adolescents in Australia
por: Whop, Lisa J, et al.
Publicado: (2021)

Implementation of Australia’s primary human papillomavirus (HPV) cervical screening program: The STakeholders Opinions of Renewal Implementation and Experiences Study
por: Brotherton, Julia M.L., et al.
Publicado: (2023)

Burden of Human papillomavirus (HPV)-related disease and potential impact of HPV vaccines in the Republic of Korea
por: Kim, Young-Tak, et al.
Publicado: (2018)

Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza Vaccines in Individuals 65 Years or Older
por: Pillsbury, Alexis J., et al.
Publicado: (2020)

A modelled analysis of the impact of COVID-19-related disruptions to HPV vaccination
por: Velentzis, Louiza S, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jalmie82j9sh6h66bfqfn7u4or